|
gptkbp:instanceOf
|
opioid
|
|
gptkbp:ATCCode
|
N02AD01
|
|
gptkbp:brand
|
Talwin
|
|
gptkbp:CASNumber
|
gptkb:76-99-3
|
|
gptkbp:cause
|
dependence
withdrawal symptoms
|
|
gptkbp:combines
|
gptkb:naloxone
|
|
gptkbp:contraindication
|
respiratory depression
acute asthma
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Sterling_Drug
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
2 to 3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasCombinationProduct
|
Pentazocine/naloxone
|
|
gptkbp:hasMolecularFormula
|
C19H27NO
|
|
gptkbp:hasSMILES
|
CC(=C)CC[C@H]1CC[C@]23Cc4ccc(O)cc4C[C@H]2N(C1)CC3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pentazocine
|
|
gptkbp:IUPACName
|
(2R,6R,11R)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-buten-1-yl)-2,6-methano-3-benzazocin-8-ol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
gptkbp:mechanismOfAction
|
kappa-opioid receptor agonist
partial mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
285.426 g/mol
|
|
gptkbp:notRecommendedFor
|
children under 12 years
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL651
4416
DB00652
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
sweating
sedation
hallucinations
|
|
gptkbp:synonym
|
Fortral
Fortwin
Pentazocinum
Sosegon
Talwin
Win 20,228
|
|
gptkbp:UNII
|
UX6OWY1DZE
|
|
gptkbp:usedFor
|
moderate to severe pain
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV_controlled_substances
|
|
gptkbp:bfsLayer
|
7
|